US2024024303A1PendingUtilityA1

Medical Treatments Based on Anamorelin

Assignee: HELSINN HEALTHCARE SAPriority: Sep 4, 2014Filed: Jun 22, 2023Published: Jan 25, 2024
Est. expirySep 4, 2034(~8.1 yrs left)· nominal 20-yr term from priority
A61K 31/454A61K 31/00A61P 1/08A61P 1/14A61P 3/00A61P 3/02A61P 5/02A61P 7/00A61P 7/06A61P 11/00A61P 21/00A61P 21/06A61P 25/20A61P 25/24A61P 25/36A61P 35/00A61P 35/04A61P 39/00A61P 39/02
79
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods of treating cancer related conditions using anamorelin are described.

Claims

exact text as granted — not AI-modified
1 . A method of treating cachexia in a human cancer patient comprising administering to said patient a therapeutically effective amount of anamorelin once daily for a therapeutically effective period of time. 
     
     
         2 . (canceled) 
     
     
         3 . (canceled) 
     
     
         4 . A method of treating fatigue resulting from cancer cachexia in a human cancer patient comprising administering to said patient a therapeutically effective amount of anamorelin on a daily basis for a therapeutically effective period of time. 
     
     
         5 . (canceled) 
     
     
         6 . (canceled) 
     
     
         7 . A method of increasing total body mass, lean body mass, and fat mass in a human patient suffering from cancer cachexia comprising administering to said patient a therapeutically effective amount of anamorelin on a daily basis for a therapeutically effective period of time. 
     
     
         8 . (canceled) 
     
     
         9 . The method of  claim 4  wherein said fatigue is caused by depression, anemia, sarcopenia, anorexia, vomiting-related malnutrition, chemo-toxicity, opioid use, and/or sleep disturbances. 
     
     
         10 . The method of  claim 1  wherein said human cancer patient is suffering from unresectable Stage III or IV non-small cell lung cancer and cachexia as defined by body weight loss greater than or equal to 5% in the previous 6 months or body mass index less than 20 kg/m 2 . 
     
     
         11 . The method of  claim 1  wherein said therapeutically effective amount of anamorelin comprises 100 mg of anamorelin HCl based on the weight of the salt. 
     
     
         12 . The method of  claim 1  wherein said therapeutically effective amount of anamorelin comprises 100 mg of anamorelin HCl based on the weight of the salt administered orally once daily at least one hour before the first meal. 
     
     
         13 . The method of  claim 1  wherein said therapeutically effective amount of anamorelin is effective to increase lean body mass of said patient. 
     
     
         14 . The method of  claim 1  wherein said therapeutically effective amount of anamorelin is effective to increase total body mass and lean body mass in said patient. 
     
     
         15 . The method of  claim 1  wherein said therapeutically effective amount of anamorelin is effective to increase total body mass, lean body mass and fat mass of said patient. 
     
     
         16 . The method of  claim 1  wherein said therapeutically effective period of time is twelve weeks. 
     
     
         17 . The method of  claim 1  wherein said therapeutically effective period of time is from 13 to 24 weeks. 
     
     
         18 . The method of  claim 1  wherein said patient has a performance status on the ECOG scale of 2 or higher. 
     
     
         19 . The method of  claim 1  wherein said patient has a squamous tumor histology. 
     
     
         20 . The method of  claim 1  wherein said cancer has metasticized. 
     
     
         21 . The method of  claim 1  wherein said patient is not receiving chemotherapy or radiotherapy. 
     
     
         22 . The method of  claim 1  wherein said patient is receiving chemotherapy or radiotherapy. 
     
     
         23 . The method of  claim 1  wherein said patient is receiving opioids and/or antiemetics.

Join the waitlist — get patent alerts

Track US2024024303A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.